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Rationale: Formoterol action may decrease progressively after its inhalation. It is unknown if
this decrease of bronchodilation following formoterol use could be associated with worsening
hyperinflation.
Objectives: To investigate whether the use of an extra daily dose of formoterol could promote
a greater reduction in lung hyperinflation and a greater improvement in inspiratory capacity
(IC) compared to usual doses.
Methods: 56 hyperinflated COPD patients were divided into two groups: F2 and F3. Basal eval-
uation was carried out after 5 days of formoterol washout. In order to evaluate the acute
effect, spirometry and body plethysmography were performed 8 h after the first formoterol
dose in both groups and repeated 1 h after an additional formoterol dose (F3) or placebo
(F2). The short-term effect was evaluated by measuring the resting lung function after a 14-
day period of formoterol t.i.d. (F3) or formoterol b.i.d. þ placebo (F2).
Measurements and main results: A second formoterol dose inhaled 8 h after the previous dose
promoted additional improvements in lung function, as demonstrated by higher IC
(118  140 mL, p < 0.001) and lower functional residual capacity (FRC) (383  367 mL,
p < 0.001). On day 15, the mean differences from baseline regarding all lung function variables
were similar between the groups.22 836718, þ39 0322 846549; fax: þ39 0322 869950.
edico.it (C.F. Donner).
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Chronic obstructive pulmonary disease (COPD) is charac-
terized by progressive airflow limitation and decreased
elasticity of the lung parenchyma resulting in hyperinflation
and gas trapping, particularly in moderate to severe
patients.1 As a consequence, during exercise, as ventilatory
demands increase in flow-limited patients, progressive air
trapping and further dynamic lung hyperinflation above the
already increased resting values is inevitable.2,3 Moreover,
it is known that measurements of forced expiratory volume
in 1st second (FEV1) is not always reliable as a surrogate
marker of pulmonary function improvement following
bronchodilator use, as reductions in lung hyperinflation in
COPD patients can occur with almost no change in FEV1.
3e7
Long-acting b2-agonists (LABA), such as formoterol, are
widely used bronchodilators in the management of COPD,
usually prescribed twice a day.8e10 However, previous
studies have shown that formoterol action may decrease
progressively 8 h after its inhalation.11e13 It is unknown if
this decrease in bronchodilation following formoterol use
could be associated with worsening hyperinflation.
The purpose of this study was to investigate whether the
administration of an extra dose of formoterol could result
in a greater increase in inspiratory capacity (IC) and
a greater reduction in static hyperinflation in two different
situations: acutely, eight hours after a previous formoterol
dose vs. placebo; and in the short-term, after a 14-day
period of formoterol t.i.d. (three times daily) vs. for-
moterol b.i.d. (twice daily).
Methods
Study design
This study was a randomized, double blind, placebo-
controlled, parallel-group trial. Randomization was con-
ducted by envelopes in blocks of four patients, with patientsbeing randomly divided into two groups: F2 and F3. The
primary outcomewas an increase frombaseline in IC ondays 1
and15. Secondaryoutcomesonday15 includedthedifference
from baseline in other lung function parameters, namely
forced vital capacity (FVC), FEV1, slow vital capacity (SVC),
residual volume (RV), functional residual capacity (FRC) and
total lung capacity (TLC).We also evaluated the improvement
in basal dyspnea scores, incidence of side effects and the use
of relief medication as secondary outcomes. The study was
approved by the local ethics committees, and all patients
signed an informed consent prior to participation.
Subjects
Patients referring to the pulmonary division of a tertiary
hospital in Brazil from July 2007 to May 2009 who met the
following inclusion criteria were invited to participate in
the study: moderate to very severe COPD according to the
Global Initiative for Obstructive Lung Disease (GOLD)
guidelines1 with post-bronchodilator FEV1  60% of pre-
dicted values, former smokers (10 pack-years), absence
of FEV1 reversibility after albuterol in spirometry, age 40
years or older, clinical stability within four weeks prior to
randomization (no occurrence of increased dyspnea,
increased sputum and/or change in sputum purulence or
change in medication use),2,14 hyperinflation as demon-
strated by FRC  130% or RV  140% or TLC  120% of
predicted values.15 Exclusion criteria were: presence of
asthma or any other active pulmonary disease and the
inability to perform pulmonary function tests or carry out
reproducible maneuvers.
Measurements
Screening visit (Day-5): Patients were screened for eligi-
bility and familiarized with the pulmonary lung function
tests, and instructed to discontinue all bronchodilators
(LABAs, tiotropium or methylxantines)(Fig. 1). They were,
Figure 1 Study design.
Effect of formoterol in COPD patients 855however, permitted to use albuterol 200 mg, via a metered
dose inhaler (MDI) device, every 6 h or as needed for
symptom relief up until 12 h before baseline examinations.
Baseline visit (Day 0): patients were randomized and
lung function tests were performed (spirometry and body
plethysmography), following discontinuation of albuterol
12 h prior. They were then sent home with instructions to
inhale a single dose of formoterol 12 mg at midnight and
return to the laboratory the next day.
Acute bronchodilator effect evaluation (Day 1): patients
underwent a body plethysmography at 8.00 a.m. in order to
detect any improvements in lung function 8 h after for-
moterol use. Following these tests, patients inhaled an
additional dose of formoterol (F3 group) or placebo
(F2 group), and lung function was reevaluated by body
plethysmography 1 h later (10.00 a.m.).Short-term effect bronchodilator evaluation (Day 15):
between days 2e14, both groups inhaled three capsules per
day in a regimen chosen to suit as best as possible their
normal daily routine (6.00e7.00 a.m., 1.00e2.00 p.m.,
8.00e9.00 p.m.), with morning and evening capsules con-
taining formoterol 12 mg in both groups, and the afternoon
capsule containing an additional dose of formoterol 12 mg
(F3 group) or placebo (F2 group). During this visit, patients
underwent spirometry and body plethysmography, with
formoterol having been withdrawn 12 h before. All for-
moterol or placebo doses were administered via a single-
dose, breath-activated device inhaler (Aerolizer), with all
capsules being provided by Mantecorp Pharmaceutical
Company; Sa˜o Paulo; Brazil.
Lung function tests: Spirometry included both forced
and slow vital capacity maneuvers, in accordance with the
Table 1 Baseline characteristics of the study population.
Variablesa F3 group
(n Z 28)
F2 group
(n Z 28)
pc
Demographics
Age (years) 64.7  7.7 64.0  7.4 0.72
Male gender,
N (%)
24 (85.7) 23 (82.1) 0.90
Body mass
index (kg/m2)
23.6  4.9 24.8  4.7 0.34
Dyspnea
mMRC 1.9  0.7 2.1  0.6 0.23
BDI 6.5  1.7 6.0  1.7 0.32
Pulmonary functionb
FVC (L) 2.68  0.61 2.60  0.72 0.66
FVC, % predicted 73  14 72  15 0.54
FEV1 (L) 1.09  0.34 1.10  0.36 0.87
FEV1, % predicted 39  13 39  9 0.90
SVC (L) 2.97  0.74 3.04  0.79 0.74
SVC, % predicted 81  15 84  16 0.51
IC (L) 1.94  0.40 1.94  0.49 0.95
IC, % predicted 68  14 69  13 0.84
FRC (L) 5.44  1.05 5.05  1.11 0.19
FRC, % predicted 162  24 153  29 0.21
RV (L) 4.41  0.93 3.93  0.79 0.04
RV, % predicted 218  47 200  43 0.13
TLC (L) 7.38  1.17 7.00  1.28 0.24
TLC, % predicted 118  14 114  16 0.29
IC/TLC, % 26.5  5.2 28.1  6.1 0.31
Definitions of abbreviations: FVC Z forced vital capacity;
FEV1Z forced expiratory volume in the 1st second; SVCZ slow
vital capacity; IC Z inspiratory capacity; FRC Z functional
residual capacity; RV Z residual volume; TLC Z total lung
capacity; mMRC Z modified Medical Research Council scale;
BDI Z Basal Dyspnea Index.
a Values presented as means  SD.
b Prebronchodilator lung function.
c Student’s t test or ManneWhitney U test according to the
type of distribution.
856 F.S. Studart et al.American Thoracic Society (ATS) criteria.16 Functional
residual capacity was measured by body plethysmography17
using a volume variable pressure body plethysmograph
(Elite Series Breeze PF System, MGC, St. Paul, USA). IC was
calculated as SVC e ERV (expiratory reserve volume).
Other measurements: Dyspnea was evaluated using the
modified Medical Research Council (mMRC) scale18 and
Baseline Dyspnea Index (BDI).19 The response to therapy in
terms of dyspnea was evaluated by the Transition Dyspnea
Index (TDI) with a 1-point difference considered as the
minimal significant difference.19 Incidence of side effects
and the use of relief medication were recorded on a diary
card. Compliance was evaluated by counting unused
capsules in both devices on day 15.
Statistical analysis
SPSS Version 16.0 statistical software was used for data
analysis (IBM, Chicago, IL). Sample size was calculated in
order to have an 80% power to detect a mean difference of
0.150 L20 in resting IC between F3 and F2 groups on day 15,
assuming two-sided aZ 5% and a standard deviation (SD) of
0.190 L according to a pilot study. The minimal number of
patients required in each group was set at 26. Descriptive
and numerical data were reported as means  SD or
means  CI 95%. Comparisons between groups were per-
formed using Student’s t test or ManneWhitney U test
according to the type of distribution. For the comparison of
variables within the same group, Paired t or Wilcoxon tests
were used as appropriate. The level of statistical signifi-
cance was set at p < 0.05 for all tests.
Results
A total of 90 patients were evaluated. Fifty-six patients
were considered eligible and subsequently entered the
study. The main reason that 34 patients were not included
was that they were unable to perform reproducible FRC
maneuvers during the screening visit. The average age of
patients was 64 years (range, 50e83), and 86% were males.
Mean FEV1 was 1.10  0.35 L (39  11% of predicted).
Hyperinflation was demonstrated by abnormally high mean
values of FRC (157  27% of predicted) and RV (209  45% of
predicted). The mean TLC was 116  15% of predicted, with
20 patients presenting TLC  120% of predicted values (9
patients in the F3 group). The sample included 11 patients
(19.6%) in GOLD Stage 2, 36 in GOLD Stage 3 (64.3%) and 9 in
GOLD Stage 4 (16.1%). The baseline characteristics of the
two treatment groups were similar (Table 1).
Day 1 e acute effect of an additional formoterol
dose vs. placebo 8 h after a previous formoterol
dose
Eight hours (8.00 a.m.) after inhalation of the first for-
moterol dose, the measurement of lung function variables
(SVC, IC, RV, FRC) still showed a statistical improvement
from baseline in both groups. These results did not differ
between the two groups. At 10.00 a.m., the group that
inhaled an extra formoterol dose showed an additionalimprovement in lung function, achieving higher SVC
(122  215 mL, p Z 0.006), higher IC (118  140 mL,
p < 0.001), lower FRC (383  367 mL, p < 0.001), lower
RV (371  460 mL, p < 0.001) and lower TLC
(263  376 mL, pZ 0.001). On the other hand, the group
that received placebo showed no statistical change in SVC,
IC, FRC, RV and TLC, with all differences between the two
groups being statistically significant (Fig. 2). The cumula-
tive bronchodilator effect from baseline after two for-
moterol doses (F3 group) compared to that after a single
formoterol dose plus placebo (F2 group) is shown in Fig. 3,
with the former showing a greater decrease in RV
(768  483 ml vs. 385  621 ml, p Z 0.014) and TLC
(386  357 mL vs.152  343 mL, p Z 0.016).Day 15 e short-term effect of formoterol t.i.d. vs.
formoterol b.i.d
Lung function: The mean differences from baseline
regarding all lung function variables were similar between
Table 2 Prebronchodilator lung function after a short-term period of formoterol t.i.d. versus usual therapy b.i.d.
Variablesa F3 group (n Z 26) F2 group (n Z 28) F3 vs. F2 (Day 15)
Baseline Day 15 Baseline Day 15 pd
FVC (L) 2.76  0.6 2.89  0.7b 2.60  0.7 2.84  0.8b 0.84
FEV1 (L) 1.12  0.3 1.20  0.4b 1.10  0.4 1.24  0.4b 0.73
FEV1/FVC 0.40  0.1 0.42  0.1 0.42  0.1 0.43  0.1 0.59
SVC (L) 3.04  0.7 3.21  0.8b 3.04  0.8 3.19  0.8b 0.93
IC (L) 1.98  0.4 2.09  0.5c 1.94  0.5 2.10  0.5b 0.97
FRC (L) 5.45  1.1 5.12  1.0b 5.05  1.1 4.83  1.1b 0.33
RV (L) 4.39  0.9 4.00  1.0b 3.93  0.8 3.74  0.9 0.32
TLC (L) 7.43  1.2 7.23  1.3 6.99  1.3 6.94  1.3 0.41
RV/TLC (%) 59.0  7.7 55.3  8.9b 56.6  7.3 54.0  8.2b 0.58
IC/TLC (%) 27.0  5.1 29.2  5.3b 28.1  6.1 30.6  6.0b 0.37
Definitions of abbreviations: FVCZ forced vital capacity; FEV1Z forced expiratory volume in the 1st second; SVCZ slow vital capacity;
IC Z inspiratory capacity; FRC Z functional residual capacity; RV Z residual volume; TLC Z total lung capacity.
a Values presented as means  SD.
b p < 0.01.
c pZ 0.06, related to differences within the same group from baseline to day 15 after formoterol treatment (paired t or Wilcoxon tests
according to the type of distribution).
d Differences on resting lung function between groups F3 and F2 on day 15 (Student’s t test).
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cally significant reduction from baseline in RV (p < 0.001)
and in TLC (p Z 0.01) (Table 2).
Dyspnea: scores in TDI scale showed a clinically signifi-
cant improvement in both F3 and F2 groups, 3.4  1.6 units
and 3.4  1.4 units, respectively, with no difference
between the two groups (p Z 0.95).
Other measurements: High treatment compliance was
observed. Only one patient in the F3 group and two patients
in the F2 group forgot to inhale one afternoon capsule
(formoterol or placebo) during the study.Figure 2 Mean difference in lung function 1 h after an
additional formoterol dose (F3 group) or placebo (F2 group)
following a previous formoterol dose inhaled 8 h earlier. Values
as means  CI 95%. Legend: C F3 group; , F2 group. Defini-
tions of abbreviations: SVC Z slow vital capacity;
ICZ inspiratory capacity; FRCZ functional residual capacity;
RVZ residual volume; TLCZ total lung capacity. p < 0.001 for
all variables (Student’s t test).Relief medication: Fourteen patients in the F3 group
(51.7%) and 15 patients in the F2 group (53.5%) did not use
any albuterol during the trial. The average number of doses
of albuterol per day was similar, 0.69  1.11 puffs and
0.70  1.58 puffs in the F3 and F2 groups, respectively
(p Z 0.78).
Side effects: these were quite rare and similar in both
groups, with no episodes of hospitalization, death,
arrhythmias or palpitation being detected or self-reported
by patients. The most common adverse event was COPD
exacerbation, which occurred in two patients in the F3
group and one patient in the F2 group, requiring a course of
antibiotics and prednisone. One patient in the F3 group
reported an episode of tremors on day 2 after using a for-
moterol dose, with no recurrence during the trial. A
headache was also reported by a patient in the F3 group;
however this cannot necessarily be associated with for-
moterol use.Discussion
There is a great deal of controversy regarding the timing
and optimal dose of inhaled b2eagonists in the treatment of
COPD. In a study by Cazzola et al. it was demonstrated that
a single high dose of formoterol is as effective as the same
dose administered in a cumulative manner, with the same
tolerability.21 In spite of this interesting finding we
preferred to test the cumulative approach, considering the
relatively advanced age of our case series, to privilege as
much as possible the aspect of safety.
The objective of this study was to evaluate the acute
and short-term effects of an additional dose of formoterol
on lung volumes in hyperinflated COPD patients. Our results
clearly demonstrate that an extra dose of formoterol
inhaled 8 h after a previous dose resulted in a greater
increase of IC and a greater reduction of hyperinflation.
However, after a 14-day treatment of formoterol t.i.d. vs.
Figure 3 Mean cumulative difference in lung function from
baseline after two formoterol doses (F3 group) compared to
that after a single formoterol dose plus placebo (F2 group).
Values as means  CI 95%. Legend: C F3 group; , F2 group.
Definitions of abbreviations: SVC Z slow vital capacity;
ICZ inspiratory capacity; FRCZ functional residual capacity;
RV Z residual volume; TLC Z total lung capacity.*p Z NS;
xp Z 0.051; yp < 0.05 (Student’s t test).
858 F.S. Studart et al.formoterol b.i.d., no difference in prebronchodilator lung
function was found between groups.
In order to evaluate the acute effect of an additional
dose of formoterol on lung volumes, patients were asked to
inhale a dose of formoterol at midnight (first dose), having
pulmonary function tests performed an hour after the
inhalation of an additional dose of formoterol (second dose)
or placebo, both administered 8 h after the first dose of
formoterol.
Significant improvements in lung function were still
observed 8 h after the inhalation of the first dose of for-
moterol in both groups, as formoterol action is expected to
last for 12 h.8,10 However, only the group that received the
second dose of formoterol evolved with a significant
increase in IC and a reduction of hyperinflation, confirming
the existence of a formoterol dose-response curve (Fig. 2).
In line with these data Cazzola et al. also observed
a greater bronchodilation effect (FEV1 increase) following
progressive doses of formoterol (12, 24 and 36 mg) in COPD
patients13 and they observed, in a subsequent study,
a dose-dependent increase in FEV1 with formoterol, with
a maximum mean increase from the 2-h value, showing that
regular treatment with formoterol does not compromise
the bronchodilator response to further cumulative inhala-
tions of formoterol.22
All these previous data support the rationale of our
study, but to the best of our knowledge, no previous studies
have evaluated this specific pharmacological strategy
(two formoterol doses, administered at an 8-h interval),
allowing a marked increase of IC of 280 mL and a decrease
of FRC of approximately 700 mL compared to the baseline.
These results are similar to findings of Celli et al. who found
an increase of 350 mL in IC and a decrease of 600 mL in FRC
at the peak bronchodilator effect of tiotropium.23 As this
additional dose of formoterol was administered in themorning (at 9.00 a.m.), with important reductions in static
hyperinflation, it is reasonable to also expect a lesser
degree of dynamic hyperinflation and, probably, a better
exercise capacity. This could be corroborated by the study
of Partridge et al. who demonstrated that formoterol/
budesonide combination, due to a more rapid onset of
bronchodilation compared to salmeterol/fluticasone, was
associated with greater improvements in the ability of
COPD patients to perform morning activities.24
On day 15, no differences in resting lung function, use of
relief medication or dyspnea scores were observed
between the two groups. One possible explanation for
these results is that the use of a third daily dose of for-
moterol is not able to promote a greater reduction in
resting airway smooth muscle tone compared to a twice-
daily dose, with any additional benefits disappearing as
soon as formoterol finishes its bronchodilator effect.
Tachyphylaxis is a possibility in this context; however as we
used a short duration protocol, and as a reduction of
formoterol-related bronchodilation effects in COPD
patients, even after longer periods of treatment,11,13 has
not been reported by other authors, this is unlikely. On the
other hand, this does not necessarily mean that a patient
from the F3 group would not benefit from this intervention.
A clinical follow up could help to discern which patients
would really benefit from the use of formoterol three times
a day. Furthermore, in the same way that an acute reduc-
tion of the lung hyperinflation was noticed in the morning
after the use of an additional dose of formoterol, it is also
possible to infer that this same benefit could occur an hour
after the use of an extra dose of formoterol in the
afternoon.
One important concern of our trial was that the use of
higher formoterol doses in elderly patients could result in
possible side effects. Our data showed that the prescription
of formoterol t.i.d. or b.i.d. appeared to be a safe inter-
vention, with the incidence of side effects being similar in
both groups. Rossi et al. did not also observe a higher
incidence of side effects in COPD patients receiving for-
moterol 24 mg b.i.d. vs. formoterol 12 mg b.i.d.11 In other
studies evaluating formoterol, no clinically significant
changes in potassium levels, heart rate, or electrocardi-
ography measurements were associated with the use of
formoterol, regardless of dose or treatment duration.25e28
Our study presents some limitations. Firstly, our findings
should not be extrapolated to other subgroups of COPD,
such as patients in GOLD stage I. It is well noted that even
mild COPD patients have some degree of air trapping which
is decreased by bronchodilator use.29,30 Similarly, COPD
patients may develop acute exacerbations; further aggra-
vating lung hyperinflation and dyspnea. Our results,
nevertheless, may not be applied to these situations, as we
analyzed only stable COPD patients. Another limitation of
our study was that we did not perform a more detailed
surveillance of possible known side effects related to for-
moterol use, which could have included, for example,
measurement of corrected QT interval in the
electrocardiogram.
In conclusion, an additional dose of formoterol was able
to reduce acutely the static hyperinflation in patients with
COPD. Hence, considering the low incidence of side effects,
it is reasonable to consider prescribing formoterol t.i.d. for
Effect of formoterol in COPD patients 859stable COPD patients who experience significant continued
breathlessness despite inhaling formoterol twice a day.
Naturally, this strategy needs to be targeted to the indi-
vidual, and in cases displaying clinical improvement, the
clinician could evaluate the possibility of maintaining it.
Other trials with a larger sample of patients could provide
better evidence in support of this strategy.
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